Abbott Laboratories Corporation

Calgene Corporation

Other

Monsanto Technology LLC

University of Oklahoma

Pradip Mukerji

Yung-Sheng Huang

Jennifer M Thurmond

Suzette Pereira

Amanda Eun-Yeong Leonard

Tapas Das

Sunita Chaudhary

Deborah Knutzon

Richard D Cummings

Pedro A Prieto

Jeffrey H Baxter

Anne C Voss

Jeffrey Harris Baxter

John J Kopchick

Kelley Wilson Moremen

James Michael Pierce

Steven Neal Anderson

David Fletcher Smith

Amanda E Leonard

Amanda Eun-Yeong Seo

Padmavathy Krishnan

Robert George Hards

Michael John Tisdale

Steven N Anderson

Shie-Ming Hwang

Lennart Hansson

Jonathan A Meulbroek

Tapas Kumar Das

Jennifer Parker-Barnes

Jim-Wen Liu

Joseph P Schaller

Debra Thomas

Linda Ann Harvey

Amanda E-y Seo

Stephen J Kirchner

Steven A Lemmel

Debra L Thomas

Suzette L Pereira

Michael J Tisdale

Disclosed are antibodies that specifically recognize &#x394;5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The &#x394;5-desaturase-specific antibodies provide improved methods of detecting &#x394;5-desaturase in a sample.

Antibodies against delta-5 desaturase and uses thereof

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., '&#x394;9-elongase') and to uses thereof. In particular, &#x394;9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) is then catalyzed by &#x394;8-desaturase and &#x394;5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Elongase gene and uses thereof

Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of &#x3b2;-hydroxy-&#x3b2;-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.

Method of using &#x3b2;-hydroxy-&#x3b2;-methylbutyrate to treat a condition

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

Compositions including beta-hydroxy-beta-methylbutyrate

Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., '&#x394;6-desaturase'). In particular, &#x394;6-desaturase may be utilized, for example, in the conversion of linoleic acid to &#x3b3;-linolenic acid and in the conversion of &#x3b1;-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;6-desaturase genes and uses thereof

Method of using &#x3b2;-hydroxy-&#x3b2;-methylbutyrate for the treatment of disease conditions

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting

Method of using beta-hydroxy-beta-methylbutyrate to treat allergies and asthma

The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to &#x3b3;-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.

Methods and compositions for synthesis of long chain polyunsaturated fatty acids

Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate

The present invention is related to isolated polynucleotides encoding a delta-8 desaturase, delta-8 desaturases encoded by the isolated polynucleotides, expression vectors containing the isolated polynucleotides, host cells containing the expression vectors and methods for producing delta-8 desaturases and polyunsaturated fatty acids.

Delta-8 desaturase genes, enzymes encoded thereby and uses thereof

HMB uses thereof

The present disclosure relates to isolated polynucleotides encoding a delta 9-elongase, delta 9-elongases encoded by the isolated polynucleotides, expression vectors comprising the isolated polynucleotides, host cells comprising the expression vectors, and methods for producing delta 9-elongase and polyunsaturated fatty acids.

&#x394;9-elongase for production of polyunsaturated fatty acid-enriched oils

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., '&#x394;5-desaturase') and at carbon 6 (i.e., '&#x394;6-desaturase') and to uses thereof. In particular, &#x394;5-desaturase may be utilized, for example, in the conversion of dihomo-&#x3b3;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &#x3b3;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;-6 desaturase and uses thereof

Growing community of inventors

Gahanna, OH, United States of America

Pradip Mukerji